{Reference Type}: Journal Article
{Title}: Baseline characteristics of patients enrolled in the EMPACT-MI trial.
{Author}: Harrington J;Udell JA;Jones WS;Anker SD;Bhatt DL;Petrie MC;Andersen KR;Sumin M;Zwiener I;Hernandez AF;Butler J;
{Journal}: Eur J Heart Fail
{Volume}: 25
{Issue}: 9
{Year}: 2023 09 25
{Factor}: 17.349
{DOI}: 10.1002/ejhf.2990
{Abstract}: Empagliflozin has been shown to reduce the risk of adverse cardiovascular outcomes in patients with type 2 diabetes and in those with heart failure. The impact of empagliflozin in post-acute myocardial infarction (AMI) patients is unknown.
The Study to Test the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction (EMPACT-MI) trial screened 6610 participants with AMI and randomized 6522 to empagliflozin or placebo in addition to standard of care. The median (interquartile) age was 64 (56-71) years and 75.1% of patients were male. Major comorbidities included hypertension (69.1%), type 2 diabetes (31.7%), prior myocardial infarction (13.0%), and atrial fibrillation (10.9%). The majority (74.3%) of patients presented with an ST-elevation myocardial infarction. Overall, 56.9% of patients had acute signs or symptoms of congestion requiring treatment and 78.3% had left ventricular systolic dysfunction with ejection fraction <45%. Clinical characteristics, including baseline demographics, rates of revascularization, and cardiovascular medications at discharge were largely comparable to recent trials of the post-AMI population.
The EMPACT-MI trial will establish the benefit and risks of empagliflozin treatment in patients with AMI.